EUVIMEDEUVIMED entdecken
Fallbericht

Intraocular Inflammation After Intravitreal Faricimab Injections: A Case Series

Yunhua Loo iD, Joshua Lim, Milton Cher Yong Chew, Anita Sook Yee Chan, Shaan Wiryasaputra

Clinical & Experimental Ophthalmology · 2026

DOI: 10.1111/ceo.70058 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Clinical & Experimental Ophthalmology, 2026. Verfasst von Yunhua Loo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Singapore National Eye Centre, Singapore. Hauptthemen laut MEDLINE: Angiogenesis Inhibitors, Uveitis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Intraocular inflammation (IOI) is a rare but potentially sight‐threatening complication that can occur after intravitreal anti‐vascular endothelial growth factor (anti‐VEGF) injections. This adverse event has been under scrutiny in recent years due to an increased incidence, particularly with some of the newer anti‐VEGF agents, such as Brolucizumab. Faricimab is a new anti‐VEGF medication that has been approved by the United States Food and Drug Administration. As it is relatively new on the market, long‐term safety data is still being collected.

Methods

This is a retrospective case series of 8 eyes in 5 patients with IOI that occurred after faricimab intravitreal injections.

Results

All patients were diagnosed with significant uveitis with anterior vitreous involvement and 4 out of the 5 patients presented subacutely with high intraocular pressure while the remaining patient presented acutely within 4 days following IVT with normal intraocular pressure. The patients received, on average, 4.875 faricimab injections prior to development of IOI and the inflammation resolved in all patients following cessation of faricimab injections and initiation of oral and topical non‐steroidal anti‐inflammatory agents and topical steroids.

Conclusion

Non‐infectious hypertensive uveitis can occur subacutely after intravitreal faricimab injections. It is imperative that intraocular pressure is promptly managed to reduce the risk of permanent glaucomatous damage. As all our patients presented with anterior vitreous involvement, it is also practical that such cases of IOI are not mistaken for infectious exogenous endophthalmitis to avoid unnecessary treatment with intravitreal antibiotics and surgery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiogenesis InhibitorsUveitisAgedFemaleHumansMaleMiddle AgedIntraocular PressureIntravitreal InjectionsRetrospective StudiesVascular Endothelial Growth Factor AVisual AcuityVitreous BodyAntibodies, Bispecific

Stichwörter der Autor:innen

Vabysmoanti‐VEGFfaricimabintraocular inflammationintravitreal injections

Substanzen

Angiogenesis InhibitorsfaricimabVascular Endothelial Growth Factor AAntibodies, Bispecific

Autor:innen und Institutionen

  • Singapore National Eye Centre, Singapore.

ORCID-Profile: Yunhua Loo

Zitieren

APA

Loo, Y., Lim, J., Chew, M. C. Y., Chan, A. S. Y., & Wiryasaputra, S. (2026). Intraocular Inflammation After Intravitreal Faricimab Injections: A Case Series. Clinical & Experimental Ophthalmology. https://doi.org/10.1111/ceo.70058

Vancouver

Loo Y, Lim J, Chew MCY, Chan ASY, Wiryasaputra S. Intraocular Inflammation After Intravitreal Faricimab Injections: A Case Series. Clinical & Experimental Ophthalmology. 2026. doi:10.1111/ceo.70058

BibTeX
@article{Loo2026,
  author = {Loo, Yunhua and Lim, Joshua and Chew, Milton Cher Yong and Chan, Anita Sook Yee and Wiryasaputra, Shaan},
  title = {Intraocular Inflammation After Intravitreal Faricimab Injections: A Case Series},
  journal = {Clinical & Experimental Ophthalmology},
  year = {2026},
  doi = {10.1111/ceo.70058}
}
Kostenlos starten →